What is dihexa chemically?

Its systematic name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and that name is a description of the molecule. At the centre sit two amino acids, tyrosine and isoleucine. At each end sits a six-carbon chain: a hexanoic acid group on the nitrogen terminus and an aminohexanoic acid amide on the other. So it is a dipeptide core wearing two fatty caps, which is why it is often described as a peptidomimetic rather than a peptide proper.

Where does dihexa come from?

It was developed in academic research at Washington State University from angiotensin IV, a short fragment within the angiotensin peptide family that had been reported to influence cognitive measures in animal models. Angiotensin IV itself is a poor research tool because it is rapidly degraded and does not readily cross into the brain. Dihexa was designed to keep the relevant activity while fixing those two problems, which is what the hexanoic caps accomplish.

Why are the hexanoic groups important?

Two reasons, both practical. They shield the peptide bonds from the peptidases that would otherwise cleave a short chain quickly, extending how long the molecule persists intact. And they make the compound considerably more lipophilic, which in the original design work was the property intended to let it cross the blood-brain barrier in animal models. A short peptide with neither property would be a poor tool for central-nervous-system research regardless of what it did at the receptor.

Is dihexa an approved medicine?

No. Dihexa holds no marketing authorisation from the MHRA, the FDA, the EMA or any comparable regulator. It is a research compound that has been studied in academic preclinical work and has not completed the clinical development that approval requires. Material sold online under this name is supplied for in-vitro laboratory research only.

No. We do not stock dihexa, there is no Certificate of Analysis for it in our library, and this guide is not an offer to supply it. It is documented here because the compound attracts steady search interest and the available information is mostly thin product copy.

What is Dihexa?

7 min read · Updated October 2026 · MY PEPTIDES Research Team

Key facts

Dihexa is a small synthetic compound developed at Washington State University from angiotensin IV, a fragment of the angiotensin peptide family. Its full chemical name, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, describes the structure: a two-residue core of tyrosine and isoleucine capped at each end with a six-carbon chain. Those caps are the point of the design, making the molecule markedly more stable and more lipophilic than the peptide fragment it came from. In preclinical neuroscience research it is studied in relation to hepatocyte growth factor and its receptor c-Met, and published rodent work has reported effects on synaptic measures and on performance in learning tasks in the models examined. Those are animal and in-vitro findings, not established effects in humans; dihexa has no marketing authorisation anywhere and is not an approved medicine. MY PEPTIDES does not stock it. General information for laboratory context only, not medical advice.

The short answer

Dihexa is not really a peptide, despite the name it is usually searched under. It is a peptidomimetic: a two-residue core of tyrosine and isoleucine with a six-carbon chain capped onto each end. The full name says exactly that, if you read it as a description rather than a label. N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide is a dipeptide wearing two fatty tails.

It came out of academic work at Washington State University, built from angiotensin IV, and in preclinical neuroscience research it is studied in relation to hepatocyte growth factor and its receptor c-Met. It is not an approved medicine anywhere and we do not sell it.

Why it was built the way it was

The starting point was angiotensin IV, a short fragment from the angiotensin family that had been reported to affect cognitive measures in animal models. As a research tool it had two disqualifying problems. It was degraded quickly by peptidases, and being a small polar peptide it did not readily reach the brain, which is awkward when the brain is the tissue you want to study.

The design response was to keep the minimal active core and solve both problems chemically. The hexanoic groups at each end do double duty: they physically obstruct the enzymes that cleave peptide bonds, and they make the molecule substantially more lipophilic, which was the property intended to improve central-nervous-system access in animal work.

This is worth understanding because it explains the compound's whole character. Dihexa is not a naturally occurring substance, and it is not a fragment of anything in the body. It is an engineered molecule whose unusual structure is a direct answer to the practical failings of the peptide it was derived from.

What the literature actually examines

The published preclinical work centres on hepatocyte growth factor and c-Met. That signalling system is best known in the context of cell growth and survival, and it also has described roles in neural tissue, including at the synapse. Rodent studies have reported effects on synaptic measures and on performance in learning and memory tasks in the models used.

Two cautions belong alongside that summary, and they are not throat-clearing.

The first is that these are animal and in-vitro findings. A compound that alters a synaptic measure in a rodent model has demonstrated something about that model. The history of neuroscience is substantially a history of compounds that did interesting things in rodents and nothing useful in people, and dihexa has not been through the clinical work that would distinguish it from that pattern.

The second is that the body of literature here is small. This is not a compound with decades of independent replication behind it; it is a relatively recent academic molecule with a limited number of groups working on it. Confidence in any finding should scale with how much independent work supports it, and in this case that is not very much.

What the research does not establish

No regulator anywhere has authorised dihexa for any human use. It has no MHRA, FDA or EMA approval, which means it has not been shown to be safe or effective in people to the standard those bodies require, and it cannot lawfully be supplied for human medicinal use in the UK.

It is also not a controlled substance under the Misuse of Drugs Act 1971. Those two facts together describe the position precisely and are frequently confused: a compound can be perfectly legal to possess for laboratory purposes while being unlawful to supply for human consumption. The Human Medicines Regulations 2012 are the relevant provision, and our guide on whether peptides are legal in the UK goes through the framework.

Material offered for sale under this name online is therefore supplied, lawfully, for in-vitro laboratory research only. Where it is offered on any other basis, that is a reason for caution about the seller rather than evidence about the compound.

Documentation matters more for an obscure compound, not less

There is a tempting assumption that quality documentation is a formality for well-known compounds and an irrelevance for obscure ones. The opposite is closer to true.

For a compound with an established market there are many suppliers, published reference spectra and a reasonable chance that a substandard batch gets noticed. For something synthesised in small quantities with little independent scrutiny, the certificate is most of what stands between you and an unknown. An unusual structure like this one, with non-standard end groups, also offers more ways for a synthesis to go subtly wrong than a plain linear peptide does.

So if you are sourcing a compound of this kind from anyone, the questions in our guide on certificates of analysis are worth more here than on a commodity peptide: is there a batch-specific analysis, what method produced the purity figure, and does the certificate identify the material rather than merely assert a percentage.

Where MY PEPTIDES stands

We do not stock this compound. There is no Certificate of Analysis for it in our library and no product page for it on this site, and this guide should not be read as an offer to supply it. If that changes, it will change by a product appearing in the catalogue with a batch certificate attached, not by a line in a guide.

The reason for saying so explicitly is that a page like this is otherwise easy to misread. Search for an obscure compound and most of the results are shops; an informational page from a supplier invites the assumption that the supplier sells it. We would rather answer the question and be clear about the answer to "can I buy it here", which is no.

What we do supply, and the documentation standard we hold it to, is set out in our guide on certificates of analysis.

The bottom line

Dihexa is an engineered peptidomimetic built from angiotensin IV, studied in a small preclinical literature in relation to hepatocyte growth factor and c-Met signalling. The animal and in-vitro findings are findings about those models. It is not an approved medicine in any jurisdiction, and we do not supply it.

All compounds referenced on this site are discussed strictly in the context of in-vitro laboratory research. Nothing here is a medicine, a supplement or a therapeutic product, nothing here describes administration to humans or animals, and this guide is general information rather than medical, legal or research advice.

Frequently asked questions

What is dihexa chemically?: Its systematic name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and that name is a description of the molecule. At the centre sit two amino acids, tyrosine and isoleucine. At each end sits a six-carbon chain: a hexanoic acid group on the nitrogen terminus and an aminohexanoic acid amide on the other. So it is a dipeptide core wearing two fatty caps, which is why it is often described as a peptidomimetic rather than a peptide proper.
Where does dihexa come from?: It was developed in academic research at Washington State University from angiotensin IV, a short fragment within the angiotensin peptide family that had been reported to influence cognitive measures in animal models. Angiotensin IV itself is a poor research tool because it is rapidly degraded and does not readily cross into the brain. Dihexa was designed to keep the relevant activity while fixing those two problems, which is what the hexanoic caps accomplish.
What is dihexa studied for in research?: The published preclinical literature examines it in relation to hepatocyte growth factor and its receptor c-Met, a signalling system involved in cell growth and survival that also has roles in neural tissue. Rodent studies have reported effects on synaptic measures and on performance in learning and memory tasks in the models used. These are observations in specific animal and in-vitro systems, dependent on model, concentration and protocol, and they are not established effects in humans.
Why are the hexanoic groups important?: Two reasons, both practical. They shield the peptide bonds from the peptidases that would otherwise cleave a short chain quickly, extending how long the molecule persists intact. And they make the compound considerably more lipophilic, which in the original design work was the property intended to let it cross the blood-brain barrier in animal models. A short peptide with neither property would be a poor tool for central-nervous-system research regardless of what it did at the receptor.
Is dihexa an approved medicine?: No. Dihexa holds no marketing authorisation from the MHRA, the FDA, the EMA or any comparable regulator. It is a research compound that has been studied in academic preclinical work and has not completed the clinical development that approval requires. Material sold online under this name is supplied for in-vitro laboratory research only.
Do you sell dihexa?: No. We do not stock dihexa, there is no Certificate of Analysis for it in our library, and this guide is not an offer to supply it. It is documented here because the compound attracts steady search interest and the available information is mostly thin product copy.